Two co-founders of Fullerton Healthcare Corporation (FHC) in Singapore face significant financial penalties after pleading guilty to falsifying entertainment expenses. Daniel Chan Pai Sheng and Michael Tan Kim Song, both 52-year-old physicians, received combined fines totalling S$160,000 on July 10 for their role in submitting inflated claims to the investment holding company. The pair's culpability came to light through a coordinated investigation that unravelled a scheme spanning multiple years and jurisdictions across Asia.
The falsified claims exceeded S$211,000, substantially inflating the actual expenses incurred by the company. Chan received the heavier penalty of S$135,000 after pleading guilty to five counts of falsification of accounts. His charges revealed a pattern where claimed entertainment expenses totalled over S$336,000, whereas genuine expenditures amounted to approximately S$125,000. This discrepancy of more than S$211,000 became the focal point of the prosecution's case, demonstrating systematic misrepresentation of company finances over an extended period.
Tan's culpability, while less extensive, was nonetheless serious. He admitted guilt to one count of falsification of accounts and received a S$25,000 fine. His involvement centred on a false entertainment claim of approximately S$82,000, when actual expenses totalled just over S$42,000. Though this particular offence contributed nearly S$40,000 to the overall inflation scheme, it formed part of the broader S$211,000 in falsified claims implicating Chan. The graduated penalties reflect the extent of each defendant's individual involvement, though both demonstrated awareness of the fraudulent activity.
Crucially, neither co-founder personally benefited from these inflated claims. Rather, the scheme was orchestrated to financially assist Collin Chiew, 58, a third party whose case remains pending resolution. Chiew held the position of chief executive at insurance broker Aon Singapore between January 2015 and July 2018, placing him in a senior commercial position during the period when the fraudulent claims were generated. Court documents have not clarified whether Chiew actually received the full amount of S$211,000, leaving a significant question mark over the ultimate destination of these diverted funds.
The genesis of this scheme emerged from Chiew's personal financial difficulties. Around 2015, Chiew approached Chan seeking financial assistance, citing pressing needs including support for his children and housing costs. Rather than declining, Chan disclosed this request to his business partner Tan, initiating a discussion that would ultimately lead to the systematic falsification of company records. This decision to help a business acquaintance through fraudulent means demonstrates how personal relationships and sympathetic circumstances can compromise professional integrity within corporate structures.
The operational mechanics of the fraud revealed sophisticated coordination across multiple jurisdictions. Chan regularly travelled to Hong Kong approximately twice monthly for FHC business purposes. Before these trips, he would contact David Sin, a third co-founder, requesting fabricated or inflated KTV receipts. Another individual, Tei Chu Pink, 46, would prepare these falsified documents. During Hong Kong visits, Chan would attend KTVs ostensibly for business development purposes, meeting potential investors alongside Sin and Tei. Upon departure, he would collect the inflated receipts, which bore no correlation to actual expenditure.
Upon returning to Singapore, Chan channelled these receipts into FHC's legitimate expense processing systems. Designated individuals within the company or its subsidiary Fullerton Health China would facilitate the claims, ultimately extracting funds that were redirected as financial assistance to Chiew. Tan possessed knowledge of many of these submissions, tacitly endorsing the arrangement through his inaction and awareness. In at least one documented instance in 2016, Tan actively conspired with Chan and Sin to orchestrate a falsified entertainment claim, elevating his role from passive knowledge to active participation.
Notably, Chan's actual behaviour at these KTV venues contradicted the fabricated receipts. On numerous occasions, he either paid substantially reduced amounts using personal cash or credit cards, or made no payments whatsoever. This inconsistency between claimed expenses and genuine outlay formed a key evidentiary element demonstrating intentional deception rather than accounting errors or misunderstandings about expense policies. The deliberate nature of these discrepancies strengthened prosecution arguments that the defendants acted with clear knowledge of their wrongdoing.
The prosecution applied for discharge not amounting to acquittal on multiple graft-related charges against both defendants, citing prosecutorial discretion. District Judge Paul Quan approved this application on July 10, effectively shelving those allegations without full resolution. This legal mechanism permits potential future prosecution should new evidence emerge, maintaining a contingent liability over the defendants. The decision to pursue falsification charges while withdrawing corruption allegations suggests the prosecution found the accounting fraud more straightforward to prove beyond reasonable doubt.
A third co-founder, David Sin, faced comparable accountability in August 2025, pleading guilty to six counts of falsification of accounts and receiving an identical S$160,000 fine. This parallel sanction indicates Sin's substantial involvement in executing the fraudulent scheme, likely reflecting his central role in generating the false receipts and coordinating the Hong Kong logistics. His nearly equivalent penalty demonstrates the court's serious view of his complicity in the systematic financial misrepresentation.
The case exposes governance vulnerabilities within rapidly expanding healthcare companies operating across multiple Asian territories. FHG, which Tan founded and directed, offered healthcare services through an extensive network of practitioners and specialists while assisting clients with insurance claim processing. Fullerton Health China, where Chan served as president, represented the company's regional expansion efforts. These operations created complex financial flows and distributed decision-making authority that the defendants exploited. The collapse of these executives' integrity fundamentally undermined the companies' control environments and stakeholder trust.
For Malaysia and the broader Southeast Asian region, this case illustrates how personal relationships and sympathetic circumstances can corrupt even established business leaders' ethical judgment. The involvement of an insurance industry executive in the beneficiary role underscores that fraudulent schemes can span multiple professional sectors. Malaysian corporate governance frameworks, already strengthened following domestic scandals, should note how multi-jurisdiction operations create opportunities for financial manipulation if oversight remains insufficient. The case reinforces that regulatory vigilance and internal controls prove essential safeguards against deliberate falsification by senior management.
